A detailed history of Atlas Capital Advisors LLC transactions in Genmab A/S stock. As of the latest transaction made, Atlas Capital Advisors LLC holds 189 shares of GMAB stock, worth $4,271. This represents 0.0% of its overall portfolio holdings.

Number of Shares
189
Previous 189 -0.0%
Holding current value
$4,271
Previous $5.65 Million 15.96%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 16, 2023

SELL
$34.88 - $43.22 $80,189 - $99,362
-2,299 Reduced 92.4%
189 $7.14 Million
Q4 2022

Feb 15, 2023

BUY
$33.8 - $47.06 $53,674 - $74,731
1,588 Added 176.44%
2,488 $105 Million
Q3 2022

Nov 08, 2022

BUY
$31.52 - $373.61 $28,368 - $336,249
900 New
900 $28.9 Million
Q2 2022

Aug 16, 2022

SELL
$26.83 - $38.57 $24,147 - $34,713
-900 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$33.66 - $40.76 $30,293 - $36,684
900 New
900 $36,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $14.9B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Atlas Capital Advisors LLC Portfolio

Follow Atlas Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atlas Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atlas Capital Advisors LLC with notifications on news.